

LISTING OF CLAIMS

The present listing of claims replaces the previous version of the claims.

Please amend the claims as follows.

1. (Currently Amended) A compound comprising a modified oligonucleotide consisting of 8 to 80 linked nucleosides nucleobases in length; and having a nucleobase sequence complementary to SEQ ID NO: 3 and wherein said compound targeted to a nucleic acid molecule encoding hydroxysteroid 11-beta dehydrogenase 1, wherein said compound specifically hybridizes with said nucleic acid molecule encoding hydroxysteroid 11-beta dehydrogenase 1 and inhibits the expression of hydroxysteroid 11-beta dehydrogenase 1 by at least 51%.
2. (Currently Amended) The compound of claim 1 which is an antisense comprising a single-stranded modified oligonucleotide.
3. (Canceled)
4. (Currently Amended) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one internucleoside linkage is a modified internucleoside linkage.
5. (Original) The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.
6. (Currently Amended) The compound of claim 2 wherein the antisense oligonucleotide at least one nucleoside comprises at least one a modified sugar moiety.
7. (Original) The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
8. (Currently Amended) The compound of claim 2 wherein at least one nucleoside the antisense oligonucleotide comprises at least one a modified nucleobase.
9. (Original) The compound of claim 8 wherein the modified nucleobase is a 5-

methylcytosine.

10. (Currently Amended) The compound of claim 2 wherein at least one nucleoside comprises the antisense oligonucleotide is a chimeric oligonucleotide.

11. (Original) A compound 8 to 80 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site on a nucleic acid molecule encoding hydroxysteroid 11-beta dehydrogenase 1.

12. (Original) A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

13. (Original) The composition of claim 12 further comprising a colloidal dispersion system.

14. (Currently Amended) The composition of claim 12 wherein the compound is an antisense modified oligonucleotide.

15. (Withdrawn) A method of inhibiting the expression of hydroxysteroid 11-beta dehydrogenase 1 in cells or tissues comprising contacting said cells or tissues with the compound of claim 1 so that expression of hydroxysteroid 11-beta dehydrogenase 1 is inhibited.

16. (Withdrawn) A method of treating an animal having a disease or condition associated with hydroxysteroid 11-beta dehydrogenase 1 comprising administering to said animal a therapeutically or prophylactically effective amount of the compound of claim 1 so that expression of hydroxysteroid 11-beta dehydrogenase 1 is inhibited.

17. (Withdrawn) The method of claim 16 wherein the disease or condition is a metabolic disorder.

18. (Withdrawn) The method of claim 17 wherein the metabolic disorder is selected from the group consisting of obesity, diabetes, atherosclerosis and hyperlipidemia.

19. (Withdrawn) The method of claim 16 wherein the disease or condition is osteoporosis.

20. (Withdrawn) The method of claim 16 wherein the disease or condition is depression.

21. (New) The compound of claim 6, wherein at least one modified sugar is a bicyclic sugar.

22. (New) The compound of claim 2, wherein the modified oligonucleotide comprises:

a gap segment consisting of linked deoxynucleosides;

a 5' wing segment consisting of linked nucleosides;

a 3' wing segment consisting of linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment and wherein each nucleoside of each wing segment comprises a modified sugar.

23. (New) The compound of claim 22, wherein the modified oligonucleotide comprises:

a gap segment consisting of ten linked deoxynucleosides;

a 5' wing segment consisting of five linked nucleosides;

a 3' wing segment consisting of five linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment, wherein each nucleoside of each wing segment comprises a 2'-O-methoxyethyl sugar; and wherein each internucleoside linkage is a phosphorothioate linkage.

24. (New) The compound of claim 22, wherein the modified oligonucleotide consists of 20 linked nucleosides.